GlassScriptPhysician profile
Arshad Mustafa
NPI 1740254499
$9,608.75
in general payments reported to CMS, 2019-2025
34 companies · $2,331 in 2025
The $2,331 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $426 · 2021: $505 · 2022: $1,992 · 2023: $2,334 · 2024: $1,806 · 2025: $2,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,423 · Education: $47.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,423.08 |
| Education | $47.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,123.71 | 2019-2025 | |
| Amgen INC. | $1,413.28 | 2020-2025 | Enbrel, Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $776.31 | 2019-2025 | |
| Janssen Biotech, INC. | $662.42 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $515.56 | 2022-2025 | |
| Ucb, INC. | $415.96 | 2022-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $415.41 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $325.52 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $293.85 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $288.13 | 2020-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.36 | 2022-2025 | Cyltezo, Spevigo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $191.12 | 2023-2025 | Lifevest |
| Organon LLC | $176.07 | 2023-2025 | Hadlima |
| Lilly USA, LLC | $170.54 | 2022-2023 | Taltz |
| Bioventus LLC | $98.45 | 2023-2025 | Durolane, Durolane, Gelsyn-3 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $88.75 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $55.28 | 2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $50.31 | 2022-2025 | Gazyva |
| Celltrion USA INC. | $47.90 | 2023 | Yuflyma |
| Mallinckrodt Hospital Products INC. | $46.90 | 2024 | Acthar |
| Supernus Pharmaceuticals, INC. | $39.36 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $29.24 | 2021 | |
| Octapharma USA, INC. | $28.44 | 2022 | |
| Merck Sharp & Dohme LLC | $25.69 | 2019-2021 | |
| Invivyd INC | $22.05 | 2025 | Pemgarda |
| Hikma Pharmaceuticals USA | $18.53 | 2020 | |
| Radius Health, INC. | $15.70 | 2025 | Tymlos |
| Fresenius Kabi USA, LLC | $15.22 | 2024 | Idacio |
| Celgene Corporation | $13.99 | 2019 | |
| Medtronic, INC. | $13.66 | 2023 | Intellis Adaptivestim |
| Mallinckrodt Enterprises LLC | $13.23 | 2019 | |
| Aurinia Pharma U.S., INC. | $11.81 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshad Mustafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.